chimerix jazz - Search News

Jazz, Chimerix

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Jazz Pharmaceuticals JAZZ announced that it has entered into a definitive agreement to acquire all the outstanding shares of clinical-stage biotech Chimerix CMRX for $8.55 per share in cash, aggregating to nearly $935 million.

GlobalData on MSN · 1d

Jazz Pharmaceuticals bids for Chimerix in $935m deal

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately $935m in cash. The deal, disclosed on Wednesday 5 March, will see Jazz pay $8.

Fierce Biotech · 1d

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO

Jazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In Play

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Chimerix downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of ...

Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel

Stifel reiterated a Buy rating and $230 price target on Jazz Pharmaceuticals (JAZZ) after the company agreed to acquire Chimerix (CMRX). The ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Jazz, Chimerix

Trending now